Blood Res.  2015 Jun;50(2):97-102. 10.5045/br.2015.50.2.97.

Maximum standardized uptake value on positron emission tomography/computed tomography predicts clinical outcome in patients with relapsed or refractory diffuse large B-cell lymphoma

Affiliations
  • 1Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
  • 2Department of Hematology-Oncology, Pusan National University Hospital, Busan, Korea. Hemon@pusan.ac.kr
  • 3Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
  • 4Department of Hematology, Seoul National University Bundang Hospital, Seongnam, Korea.
  • 5Department of Hematology, Gachon University Gil Hospital, Incheon, Korea.
  • 6Department of Hematology-Oncology, Pusan National University Yangsan Hospital, Yangsan, Korea.
  • 7Department of Nuclear Medicine, Pusan National University Hospital, Busan, Korea.
  • 8Department of Pathology, Pusan National University Yangsan Hospital, Yangsan, Korea.

Abstract

BACKGROUND
Few clinical studies have clarified the prognostic factors that affect clinical outcomes for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after immunochemotherapy.
METHODS
A total of 158 patients with relapsed or refractory DLBCL were enrolled. All patients underwent positron emission tomography/computed tomography (PET/CT) before and after salvage therapy. All enrolled patients previously received the ifosfamide, carboplatin, and etoposide regimen. Clinical outcomes were compared according to several factors (age > or = 65 years, low age-adjusted International Prognostic Index [aa-IPI], maximum standardized uptake value [SUVmax] <6.0 on PET/CT, time to relapse > or =12 months, complete response after salvage therapy). A low aa-IPI, SUVmax <6.0, and time to relapse > or = 12 months were independent prognostic factors for survival.
RESULTS
In univariate analysis and multivariate analysis, SUVmax below 6.0 (P<0.001 for progression-free survival (PFS), P<0.001 for overall survival (OS)) and low aa-IPI (P<0.001 for PFS, P<0.001 for OS) were independent prognostic factors associated with favorable outcome.
CONCLUSION
The aa-IPI and initial SUVmax were powerful prognostic factors in patients with relapsed or refractory DLBCL.

Keyword

Positron emission tomography; SUVmax; aa-IPI
Full Text Links
  • BR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr